Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Sponsor: Children's Oncology Group
Listed as NCT01371656, this PHASE3 trial focuses on Acute Leukemias of Ambiguous Lineage and Bacterial Infection and remains completed. Sponsored by Children's Oncology Group, it has been updated 13 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .